Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.50 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886322 | 1.00 | PDE4B (0.51) | PDE4BHDAC1HDAC8HDAC6MLLT1 | |
| SCHEMBL4894837 | 0.80 | HSD17B10 (0.46) | ALDH1A1THRB | |
| SCHEMBL4898393 | 0.80 | HSD17B10 (0.46) | ALDH1A1THRB | |
| SCHEMBL12563444 | 0.78 | HDAC1 (0.45) | PDE4BHDAC1HDAC8HDAC6PDE2A | |
| SCHEMBL12605025 | 0.78 | HDAC1 (0.44) | PDE4BHDAC1HDAC8HDAC6PDE2A | |
| SCHEMBL4897161 | 0.77 | HSD17B1 (0.57) | PDE4BHDAC1HDAC8HDAC6HSD17B1 | |
| SCHEMBL4897783 | 0.77 | HDAC1 (0.55) | PDE4BHDAC1HDAC8HDAC6HSD17B1 | |
| SCHEMBL12563466 | 0.76 | HDAC1 (0.58) | PDE4BHDAC1HDAC8HDAC6PDE2A | |
| SCHEMBL12697484 | 0.76 | HDAC1 (0.41) | PDE4BHDAC1HDAC8HDAC6PDE2A | |
| SCHEMBL1660660 | 0.76 | HDAC1 (0.41) | PDE4BHDAC1HDAC8HDAC6PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815924-B2 | Heterocyclic carbonyl compounds | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | MERCK PATENT GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090882-A1 | Inhibitors of kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK); diabetes, obesity, metabolic syndrome, systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, fibroses and inflammatory processes; amide-substituted imidazoles, oxazoles, thiazoles, or furans | SGK1, SGK2, SGK3 | PDE4B 3681/4885HDAC1 306/4885HDAC8 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.